vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and FIRSTSUN CAPITAL BANCORP (FSUN). Click either name above to swap in a different company.
FIRSTSUN CAPITAL BANCORP is the larger business by last-quarter revenue ($110.0M vs $83.5M, roughly 1.3× BillionToOne, Inc.). FIRSTSUN CAPITAL BANCORP runs the higher net margin — 19.6% vs 6.8%, a 12.8% gap on every dollar of revenue.
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
BLLN vs FSUN — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $110.0M |
| Net Profit | $5.7M | $21.6M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | — |
| Net Margin | 6.8% | 19.6% |
| Revenue YoY | 117.4% | — |
| Net Profit YoY | 138.3% | -8.4% |
| EPS (diluted) | $0.10 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $110.0M | ||
| Q4 25 | — | $110.2M | ||
| Q3 25 | $83.5M | $107.3M | ||
| Q2 25 | — | $105.6M | ||
| Q1 25 | — | $96.2M | ||
| Q4 24 | — | $98.7M | ||
| Q3 24 | $38.4M | $98.2M | ||
| Q2 24 | — | $96.2M |
| Q1 26 | — | $21.6M | ||
| Q4 25 | — | $24.8M | ||
| Q3 25 | $5.7M | $23.2M | ||
| Q2 25 | — | $26.4M | ||
| Q1 25 | — | $23.6M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | $-14.9M | $22.4M | ||
| Q2 24 | — | $24.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 29.0% | ||
| Q3 25 | 11.5% | 26.4% | ||
| Q2 25 | — | 31.2% | ||
| Q1 25 | — | 30.9% | ||
| Q4 24 | — | 20.4% | ||
| Q3 24 | -32.9% | 29.1% | ||
| Q2 24 | — | 32.3% |
| Q1 26 | — | 19.6% | ||
| Q4 25 | — | 22.5% | ||
| Q3 25 | 6.8% | 21.6% | ||
| Q2 25 | — | 25.0% | ||
| Q1 25 | — | 24.5% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | -38.8% | 22.8% | ||
| Q2 24 | — | 25.5% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | — | $0.89 | ||
| Q3 25 | $0.10 | $0.82 | ||
| Q2 25 | — | $0.93 | ||
| Q1 25 | — | $0.83 | ||
| Q4 24 | — | $0.57 | ||
| Q3 24 | $-1.47 | $0.79 | ||
| Q2 24 | — | $0.88 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $413.7M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $1.2B |
| Total Assets | $327.5M | $8.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $413.7M | ||
| Q4 25 | — | $652.6M | ||
| Q3 25 | $195.2M | $659.9M | ||
| Q2 25 | — | $785.1M | ||
| Q1 25 | — | $621.4M | ||
| Q4 24 | — | $615.9M | ||
| Q3 24 | — | $573.7M | ||
| Q2 24 | — | $535.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | $-239.5M | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | $-242.9M | $1.0B | ||
| Q2 24 | — | $996.6M |
| Q1 26 | — | $8.6B | ||
| Q4 25 | — | $8.5B | ||
| Q3 25 | $327.5M | $8.5B | ||
| Q2 25 | — | $8.4B | ||
| Q1 25 | — | $8.2B | ||
| Q4 24 | — | $8.1B | ||
| Q3 24 | — | $8.1B | ||
| Q2 24 | — | $8.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $111.5M | ||
| Q3 25 | $13.8M | $49.4M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $26.4M | ||
| Q4 24 | — | $101.1M | ||
| Q3 24 | — | $48.1M | ||
| Q2 24 | — | $20.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $104.0M | ||
| Q3 25 | $6.5M | $47.6M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $24.3M | ||
| Q4 24 | — | $95.7M | ||
| Q3 24 | — | $47.1M | ||
| Q2 24 | — | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 94.3% | ||
| Q3 25 | 7.7% | 44.4% | ||
| Q2 25 | — | 12.3% | ||
| Q1 25 | — | 25.3% | ||
| Q4 24 | — | 97.0% | ||
| Q3 24 | — | 47.9% | ||
| Q2 24 | — | 20.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.8% | ||
| Q3 25 | 8.8% | 1.6% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 5.5% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | — | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.49× | ||
| Q3 25 | 2.42× | 2.13× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 6.18× | ||
| Q3 24 | — | 2.15× | ||
| Q2 24 | — | 0.85× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
